Prions and Transmissible Spongiform Encephalopathy (TSE) Chemotherapeutics: A Common Mechanism for Anti-TSE Compounds?
Accounts of Chemical Research
American Chemical Society
No validated treatments exist for transmissible spongiform encephalopathies (TSEs or prion diseases) in humans or livestock. The search for TSE therapeutics is complicated by persistent uncertainties about the nature of mammalian prions and their pathogenic mechanisms. In pursuit of anti-TSE drugs, we and others have focused primarily on blocking conversion of normal prion protein, PrP^C, to the TSE-associated isoform, PrP^Sc. Recently developed high-throughput screens have hastened the identification of new inhibitors with strong in vivo anti-TSE activities such as porphyrins, phthalocyanines, and phosphorthioated oligonucleotides. New routes of administration have enhanced beneficial effects against established brain infections. Several different classes of TSE inhibitors share structural similarities, compete for the same site(s) on PrP^C, and induce the clustering and internalization of PrP^C from the cell surface. These activities may represent a common mechanism of action for these anti-TSE compounds.
Caughey, B., W.S. Caughey, D.A. Kocisko, K.S. Lee, J.R. Silveira, and J.D. Morrey 2006. Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: A common mechanism for anti-TSE compounds?. Acc. Chem. Res., 39(9): 646-53.
Originally published by the American Chemical Society. Publisher's PDF and HTML fulltext available through remote link.